Leading Veterinary Academic, Dr. Jane Sykes, Joins LexaGene Board of Directors
November 15 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a molecular diagnostics company
that has commercialized an instrument for automated multiplex PCR
testing, today announced Dr. Jane Sykes, BVSc(Hons), PhD, MBA,
DipACVIM (Small Animal Internal Medicine) has joined the LexaGene
Board of Directors.
Dr. Sykes is the Executive Director of Innovation and
Entrepreneurship, School of Veterinary Medicine at the University
of California, Davis (UC Davis) and Professor of Small Animal
Internal Medicine (Infectious Diseases). For more than 20 years,
Dr. Sykes has held numerous positions at UC Davis including Chief
Veterinary Medical Officer/Associate Dean of Veterinary Medical
Center Operations, Director of Small Animal Clinical Services, and
Infection Control Officer for the Veterinary Medical Teaching
Hospital. She has also served as the Associate Editor for the
Journal of Veterinary Internal Medicine and is currently
volunteering her time as the incoming President for the American
College of Veterinary Medicine (ACVIM). Dr. Sykes received her
veterinary degree and PhD at the University of Melbourne and her
MBA from the University of Georgia. She founded the International
Society for Companion Animal Infectious Diseases (ISCAID) in
2006.
Dr. Jack Regan, LexaGene’s CEO and Founder stated, “Dr. Sykes an
entrepreneurial leader, whose education and focus on animal care,
including infectious diseases, will be a tremendous asset to our
company, our science, and our future. Her deep experience, academic
acumen, and veterinary perspective make her the perfect LexaGene
champion. She will be an excellent resource and partner to our
company as we continue to scale our business and make headway
bringing in-clinic diagnostic PCR testing to veterinary practices
across the country.”
Dr. Jane Sykes commented, “I’m excited to join LexaGene’s Board
of Directors. I share Dr. Regan’s convictions and passion for
point-of-care PCR testing and the passion for improving companion
animal care as we roll out the MiQLab to the veterinary market. I’m
thrilled to serve on LexaGene’s board of directors and work
alongside the other board members as we improve shareholder
value.”
Dr. Sykes board term began on November 8, 2021. Dr. Sykes
replaces Dr. Manohar Furtado, who has taken on a new role for a
Company that requires 100 percent of his time. Dr. Regan commented,
“I’m extremely grateful for Manohar’s mentorship and his
contributions to our board and to LexaGene. Manohar has been an
excellent board member and I wish him the greatest success in his
new endeavor.”
On November 10th, pursuant to the Company’s omnibus stock option
plan, the Company announced that the board of directors granted Dr.
Sykes 100,000 non-statutory stock options (NSOs) to acquire common
shares of the Company with a strike price of CAD $0.66/NSO. Ten
percent of these stock options vested on the grant date, with 15
percent vesting every six months thereafter. The expiry of the NSOs
is on November 11th, 2031. In addition, the Company announced that
the board of directors granted Dr. Sykes 100,000 restricted share
units (RSUs). Ten percent of these RSUs will vest on May 11, 2023
with 10 percent vesting each month thereafter, expiring on February
11, 2024.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate & Media Contact:
Gail Winslow
Director of Marketing
gwinslow@lexagene.com
978.482.6237
Investors:
ir@lexagene.com
800.215.1824
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024